New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
10:07 EDTAGN, VAR, ETFC, AMTD, SCHW, CHMT, ALKSOn The Fly: Analysts Initiation Summary
Today's noteworthy initiations include: Allergan (AGN) initiated with a Buy at SunTrust...Varian Medical (VAR) initiated with a Buy at Benchmark Co. and with a Buy at SunTrust...E-Trade (ETFC) initiated with a Neutral at Compass Point...TD Ameritrade (AMTD) initiated with a Neutral at Compass Point...Charles Schwab (SCHW) initiated with a Neutral at Compass Point...Chemtura (CHMT) initiated with a Buy at KeyBanc...Alkermes (ALKS) initiated with a Buy at Mizuho.
News For AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS From The Last 14 Days
Check below for free stories on AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 18, 2014
08:31 EDTVARVarian Medical board authorizes repurchase of 6M shares through 2015
Subscribe for More Information
07:57 EDTAGNCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 15, 2014
17:03 EDTAGNValeant extends offer to acquire Allergan
Valeant Pharmaceuticals (VRX) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31. The exchange offer was previously scheduled to expire August 15. All other terms and conditions of the exchange offer remain unchanged.
14:14 EDTAGNValeant being probed by IRS after Biovail deal, FT says
Subscribe for More Information
09:45 EDTAGNEvent-driven funds, Pershing own over 20% of Allergan, CNBC reports
Event-driven hedge funds and Pershing Square owned over 20% of Allergan as of June 30, CNBC's David Faber reports. Valeant (VRX) and Pershing are seen as getting the over 30% to call a special meeting, Faber adds.
August 14, 2014
17:16 EDTAGNPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:02 EDTAGNPershing Square gives quarterly update on stakes
Subscribe for More Information
17:00 EDTCHMTGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
14:28 EDTAGNAckman says Pershing, Valeant took no tender steps before buying Allergan shares
Bill Ackman made the statement to CNBC's Scott Wapner regarding his fund and Valeant's (VRX) pursuit of Allergan (AGN). Note that the Wall Street Journal reported earlier that the SEC is investigating Valeant and Pershing's pursuit of Allergan.
13:48 EDTAGNValeant, Pershing joint bid for Allergan being probed by SEC, WSJ says
Subscribe for More Information
13:22 EDTAGNValeant, Pershing joint bid for Allergan being probed by SEC, DJ says
Subscribe for More Information
10:57 EDTETFC, SCHW, AMTDCharles Schwab DARTs momentum continued in July, says UBS
UBS noted that Charles Schwab's (SCHW) daily average revenue trades, or DARTS, increased 3% sequentially in July, adding that if the acceleration can continue deeper into the quarter that the firm sees upside potential relative to estimates. However, UBS also pointed out that Schwab's 3% sequential pickup is below what peers TD Ameritrade (AMTD) and E-Trade (ETFC) reported in recent days. UBS maintain its Buy rating and $32 price target on shares of Charles Schwab.
10:05 EDTAMTD, ETFC, SCHWOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:47 EDTSCHWCharles Schwab reports July-end total client assets $2.38T
Subscribe for More Information
08:06 EDTETFCE-Trade reports July DARTs of 153,671, up 5% from June
Subscribe for More Information
07:47 EDTSCHW, ETFC, AMTDDeutsche Bank hosts an analyst Online Brokers/Industry conference call
Subscribe for More Information
06:40 EDTETFCE-Trade initiated with a Hold at Deutsche Bank
Subscribe for More Information
06:40 EDTAMTDTD Ameritrade initiated with a Buy at Deutsche Bank
Subscribe for More Information
06:40 EDTSCHWCharles Schwab initiated with a Buy at Deutsche Bank
Subscribe for More Information
August 13, 2014
16:32 EDTAGNAllergan acquires LiRIS program from TARIS Biomedical
Allergan and TARIS Holdings announced that Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedicalís lead program, LiRIS, which is currently in Phase 2 trials for the treatment of interstitial cystitis / bladder pain syndrome. Allergan paid $67.5M in cash upfront, subject to certain adjustments and holdbacks. Allergan has also agreed to pay up to an aggregate of $295M in development milestone payments and up to an aggregate of $225M in commercial milestone payments. Prior to the closing of this transaction, TARIS spun out certain assets, including pipeline programs and intellectual property related to TARISí platform technology, to a new company funded by TARIS shareholders.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use